Merck to buy eye-focused drug developer EyeBio for as much as $3 billion
(Reuters) – Merck on Wednesday agreed to acquire privately held biotech EyeBio for as much as $3 billion, the latest in a string of deals by the US drugmaker to bolster its future growth. It agreed to pay $1.3 billion in cash and another $1.7 billion in future milestone-based payments for EyeBio, and will gain…